These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

192 related items for PubMed ID: 10070972

  • 1. Ret-mediated mitogenesis requires Src kinase activity.
    Melillo RM, Barone MV, Lupoli G, Cirafici AM, Carlomagno F, Visconti R, Matoskova B, Di Fiore PP, Vecchio G, Fusco A, Santoro M.
    Cancer Res; 1999 Mar 01; 59(5):1120-6. PubMed ID: 10070972
    [Abstract] [Full Text] [Related]

  • 2. Glial cell line-derived neurotrophic factor differentially stimulates ret mutants associated with the multiple endocrine neoplasia type 2 syndromes and Hirschsprung's disease.
    Carlomagno F, Melillo RM, Visconti R, Salvatore G, De Vita G, Lupoli G, Yu Y, Jing S, Vecchio G, Fusco A, Santoro M.
    Endocrinology; 1998 Aug 01; 139(8):3613-9. PubMed ID: 9681515
    [Abstract] [Full Text] [Related]

  • 3. Grb2 binding to the different isoforms of Ret tyrosine kinase.
    Alberti L, Borrello MG, Ghizzoni S, Torriti F, Rizzetti MG, Pierotti MA.
    Oncogene; 1998 Sep 03; 17(9):1079-87. PubMed ID: 9764818
    [Abstract] [Full Text] [Related]

  • 4. Signalling of the Ret receptor tyrosine kinase through the c-Jun NH2-terminal protein kinases (JNKS): evidence for a divergence of the ERKs and JNKs pathways induced by Ret.
    Chiariello M, Visconti R, Carlomagno F, Melillo RM, Bucci C, de Franciscis V, Fox GM, Jing S, Coso OA, Gutkind JS, Fusco A, Santoro M.
    Oncogene; 1998 May 14; 16(19):2435-45. PubMed ID: 9627110
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Docking protein FRS2 links the protein tyrosine kinase RET and its oncogenic forms with the mitogen-activated protein kinase signaling cascade.
    Melillo RM, Santoro M, Ong SH, Billaud M, Fusco A, Hadari YR, Schlessinger J, Lax I.
    Mol Cell Biol; 2001 Jul 14; 21(13):4177-87. PubMed ID: 11390647
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Characterization of Ret-Shc-Grb2 complex induced by GDNF, MEN 2A, and MEN 2B mutations.
    Ohiwa M, Murakami H, Iwashita T, Asai N, Iwata Y, Imai T, Funahashi H, Takagi H, Takahashi M.
    Biochem Biophys Res Commun; 1997 Aug 28; 237(3):747-51. PubMed ID: 9299438
    [Abstract] [Full Text] [Related]

  • 9. Tyrosine 1062 of RET-MEN2A mediates activation of Akt (protein kinase B) and mitogen-activated protein kinase pathways leading to PC12 cell survival.
    De Vita G, Melillo RM, Carlomagno F, Visconti R, Castellone MD, Bellacosa A, Billaud M, Fusco A, Tsichlis PN, Santoro M.
    Cancer Res; 2000 Jul 15; 60(14):3727-31. PubMed ID: 10919641
    [Abstract] [Full Text] [Related]

  • 10. GDNF triggers a novel ret-independent Src kinase family-coupled signaling via a GPI-linked GDNF receptor alpha1.
    Poteryaev D, Titievsky A, Sun YF, Thomas-Crusells J, Lindahl M, Billaud M, Arumäe U, Saarma M.
    FEBS Lett; 1999 Dec 10; 463(1-2):63-6. PubMed ID: 10601639
    [Abstract] [Full Text] [Related]

  • 11. RET-familial medullary thyroid carcinoma mutants Y791F and S891A activate a Src/JAK/STAT3 pathway, independent of glial cell line-derived neurotrophic factor.
    Plaza Menacho I, Koster R, van der Sloot AM, Quax WJ, Osinga J, van der Sluis T, Hollema H, Burzynski GM, Gimm O, Buys CH, Eggen BJ, Hofstra RM.
    Cancer Res; 2005 Mar 01; 65(5):1729-37. PubMed ID: 15753368
    [Abstract] [Full Text] [Related]

  • 12. Key role of Shc signaling in the transforming pathway triggered by Ret/ptc2 oncoprotein.
    Mercalli E, Ghizzoni S, Arighi E, Alberti L, Sangregorio R, Radice MT, Gishizky ML, Pierotti MA, Borrello MG.
    Oncogene; 2001 Jun 14; 20(27):3475-85. PubMed ID: 11429694
    [Abstract] [Full Text] [Related]

  • 13. Two distinct mutations of the RET receptor causing Hirschsprung's disease impair the binding of signalling effectors to a multifunctional docking site.
    Geneste O, Bidaud C, De Vita G, Hofstra RM, Tartare-Deckert S, Buys CH, Lenoir GM, Santoro M, Billaud M.
    Hum Mol Genet; 1999 Oct 14; 8(11):1989-99. PubMed ID: 10484767
    [Abstract] [Full Text] [Related]

  • 14. The full oncogenic activity of Ret/ptc2 depends on tyrosine 539, a docking site for phospholipase Cgamma.
    Borrello MG, Alberti L, Arighi E, Bongarzone I, Battistini C, Bardelli A, Pasini B, Piutti C, Rizzetti MG, Mondellini P, Radice MT, Pierotti MA.
    Mol Cell Biol; 1996 May 14; 16(5):2151-63. PubMed ID: 8628282
    [Abstract] [Full Text] [Related]

  • 15. Tissue-specific carcinogenesis in transgenic mice expressing the RET proto-oncogene with a multiple endocrine neoplasia type 2A mutation.
    Kawai K, Iwashita T, Murakami H, Hiraiwa N, Yoshiki A, Kusakabe M, Ono K, Iida K, Nakayama A, Takahashi M.
    Cancer Res; 2000 Sep 15; 60(18):5254-60. PubMed ID: 11016655
    [Abstract] [Full Text] [Related]

  • 16. Characterization of intracellular signals via tyrosine 1062 in RET activated by glial cell line-derived neurotrophic factor.
    Hayashi H, Ichihara M, Iwashita T, Murakami H, Shimono Y, Kawai K, Kurokawa K, Murakumo Y, Imai T, Funahashi H, Nakao A, Takahashi M.
    Oncogene; 2000 Sep 14; 19(39):4469-75. PubMed ID: 11002419
    [Abstract] [Full Text] [Related]

  • 17. Increased in vivo phosphorylation of ret tyrosine 1062 is a potential pathogenetic mechanism of multiple endocrine neoplasia type 2B.
    Salvatore D, Melillo RM, Monaco C, Visconti R, Fenzi G, Vecchio G, Fusco A, Santoro M.
    Cancer Res; 2001 Feb 15; 61(4):1426-31. PubMed ID: 11245446
    [Abstract] [Full Text] [Related]

  • 18. Enhanced phosphatidylinositol 3-kinase activity and high phosphorylation state of its downstream signalling molecules mediated by ret with the MEN 2B mutation.
    Murakami H, Iwashita T, Asai N, Shimono Y, Iwata Y, Kawai K, Takahashi M.
    Biochem Biophys Res Commun; 1999 Aug 19; 262(1):68-75. PubMed ID: 10448070
    [Abstract] [Full Text] [Related]

  • 19. RET/PTC (rearranged in transformation/papillary thyroid carcinomas) tyrosine kinase phosphorylates and activates phosphoinositide-dependent kinase 1 (PDK1): an alternative phosphatidylinositol 3-kinase-independent pathway to activate PDK1.
    Kim DW, Hwang JH, Suh JM, Kim H, Song JH, Hwang ES, Hwang IY, Park KC, Chung HK, Kim JM, Park J, Hemmings BA, Shong M.
    Mol Endocrinol; 2003 Jul 19; 17(7):1382-94. PubMed ID: 12738763
    [Abstract] [Full Text] [Related]

  • 20. Identification of SNT/FRS2 docking site on RET receptor tyrosine kinase and its role for signal transduction.
    Kurokawa K, Iwashita T, Murakami H, Hayashi H, Kawai K, Takahashi M.
    Oncogene; 2001 Apr 12; 20(16):1929-38. PubMed ID: 11360177
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.